These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10075589)

  • 1. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients.
    Vallhonrat H; Williams WW; Cosimi AB; Tolkoff-Rubin N; Ginns LC; Wain JC; Preffer F; Olszak I; Wee S; Delmonico FL; Pascual M
    Transplantation; 1999 Jan; 67(2):253-8. PubMed ID: 10075589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid activation of the alternative pathway of complement by extracorporeal membrane oxygenation.
    Vallhonrat H; Swinford RD; Ingelfinger JR; Williams WW; Ryan DP; Tolkoff-Rubin N; Cosimi AB; Pascual M
    ASAIO J; 1999; 45(1):113-4. PubMed ID: 9952020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement activation in severe Plasmodium falciparum malaria.
    Wenisch C; Spitzauer S; Florris-Linau K; Rumpold H; Vannaphan S; Parschalk B; Graninger W; Looareesuwan S
    Clin Immunol Immunopathol; 1997 Nov; 85(2):166-71. PubMed ID: 9344699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of the membrane attack complex during haemodialysis: impact of classical and alternative pathway components.
    Hauser AC; Derfler K; Stockenhuber F; Janata O; Balcke P
    Clin Sci (Lond); 1990 Nov; 79(5):471-6. PubMed ID: 2174314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.
    Brodeur JP; Ruddy S; Schwartz LB; Moxley G
    Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in C3, C4, factor B, and related metabolites in septic shock.
    Lin RY; Astiz ME; Saxon JC; Saha DC; Rackow EC
    Clin Immunol Immunopathol; 1993 Nov; 69(2):136-42. PubMed ID: 8403550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease.
    Rostagno A; Revesz T; Lashley T; Tomidokoro Y; Magnotti L; Braendgaard H; Plant G; Bojsen-Møller M; Holton J; Frangione B; Ghiso J
    J Biol Chem; 2002 Dec; 277(51):49782-90. PubMed ID: 12388551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of the complement degradation product C4d in renal allografts: diagnostic and therapeutic implications.
    Nickeleit V; Zeiler M; Gudat F; Thiel G; Mihatsch MJ
    J Am Soc Nephrol; 2002 Jan; 13(1):242-251. PubMed ID: 11752044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation during OKT3 treatment: a possible explanation for respiratory side effects.
    Raasveld MH; Bemelman FJ; Schellekens PT; van Diepen FN; van Dongen A; van Royen EA; Hack CE; ten Berge IJ
    Kidney Int; 1993 May; 43(5):1140-9. PubMed ID: 8510394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction immunosuppression for lung transplantation with OKT3.
    Wain JC; Wright CD; Ryan DP; Zorb SL; Mathisen DJ; Ginns LC
    Ann Thorac Surg; 1999 Jan; 67(1):187-93. PubMed ID: 10086547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pleural SC5b-9 in differential diagnosis of tuberculous, malignant, and other effusions.
    Hara N; Abe M; Inuzuka S; Kawarada Y; Shigematsu N
    Chest; 1992 Oct; 102(4):1060-4. PubMed ID: 1395743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation during CAPD.
    Young GA; Kendall S; Brownjohn AM
    Nephrol Dial Transplant; 1993; 8(12):1372-5. PubMed ID: 8159307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes.
    Vachino G; Gelfand JA; Atkins MB; Tamerius JD; Demchak P; Mier JW
    Blood; 1991 Nov; 78(10):2505-13. PubMed ID: 1824247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.
    Ferraris JR; Ferraris V; Acquier AB; Sorroche PB; Saez MS; Ginaca A; Mendez CF
    Clin Exp Immunol; 2015 Jul; 181(1):118-25. PubMed ID: 25677399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement.
    Buyon JP; Tamerius J; Belmont HM; Abramson SB
    Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation products in plasma after heart transplantation in humans.
    Vallhonrat H; Williams WW; Dec GW; Keck S; Schoenfeld D; Cosimi AB; Pascual M
    Transplantation; 2001 May; 71(9):1308-11. PubMed ID: 11397968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the complement system by different autologous transfusion devices: an in vitro study.
    Tylman M; Bengtson JP; Bengtsson A
    Transfusion; 2003 Mar; 43(3):395-9. PubMed ID: 12675727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.